|
|
 |
|
Viewing report
|
|
|
|
Forecast Insight: Parkinson's Disease - Market Upgrade following Evidence of Disease Slowing with Azilect
Datamonitor, Sep 2008, Pages: 123
Stimulated by evidence of disease slowing with Teva/Lundbecks Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinsons disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.
Scope
- This report gives a strategic analysis of the likely impact that recent events will have on the future Parkinsons disease market
- Includes Parkinsons disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
- Provides a global market snapshot by including Parkinsons disease-specific sales analysis for leading brands outside the seven major markets
- Key conclusions are supported by key opinion leader comment
Highlights of this title
Datamonitor has upgraded its forecasts of Teva/Lundbecks Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinsons disease drug at this time.
GlaxoSmithKlines Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheims Mirapex (pramipexole).
Datamonitor has downgraded its sales forecasts of UCBs Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCBs misfortune.
Key reasons to purchase this title
- Understand the impact of recent and anticipated events on the Parkinsons disease market during the forecast period 2008 to 2017
- Quantify the current size of the seven major markets and the trends in the rest of the world
- Assess the impact of events, such as patent expiries and new product launches, on the Parkinsons disease-specific sales of key brands
Customers who bought this item also bought
Infectious Disease Diagnostics Markets in sub-Saharan Africa
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Oxford Handbook of Evolution in Health and Disease
Trial TRAX - Alzheimers Disease - Clinical Trial Monitoring Brief
Wireless Based Disease Management
Alzheimers and Parkinsons Disease - Global Strategic Business Report
Target Product Profiles 2008: Physician Insights on Key Attributes - Crohns Disease
Disease and Therapy Review: Parkinsons Disease
|
|
|
|
